BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Pulse Biosciences (PLSE)Pulse BiosciencesCompany update

164 evaluable patients enrolled across 15 clinical sites HAYWARD, Calif. --(BUSINESS WIRE)--Oct. 7, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF

Related news

PLSEPulse Biosciences2026-09-15 11:00 EST

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

PLSEPulse Biosciences2026-07-29 11:00 EST

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

HYPRHyperfine2026-09-15 12:15 EST

Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

VTAKCatheter Precision2026-08-27 12:00 EST

Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany

ICCMIceCure Medical2026-08-06 12:05 EST

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

HYPRHyperfine2026-07-30 12:15 EST

Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care

ICCMIceCure Medical2026-07-27 12:32 EST

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

ICUSeaStar Medical2026-10-07 12:16 EST

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

CVRXCVRx2026-09-29 20:30 EST

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

IARTIntegra LifeSciences2026-09-25 13:05 EST

Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026

View all latest news

Pulse Biosciences

Nanosecond Pulsed-Field Ablation Pulse Biosciences develops the nPulse platform, which delivers proprietary nanosecond pulsed-field energy to ablate targeted tissue. The technology is designed to create nonthermal cellular effects and is being evaluated in cardiac and soft-tissue applications. Cardiac Catheter System The nPulse Cardiac...

Recent company news

PLSEPulse Biosciences2026-10-07 11:00 EST

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

PLSEPulse Biosciences2026-09-15 11:00 EST

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

PLSEPulse Biosciences2026-09-04 11:00 EST

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PLSEPulse Biosciences2026-08-18 11:00 EST

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

Stock data

Close
49.75 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States